Larimar Therapeutics (LRMR) Liabilities and Shareholders Equity: 2013-2020
Historic Liabilities and Shareholders Equity for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to $114.0 million.
- Larimar Therapeutics' Liabilities and Shareholders Equity rose 22.68% to $114.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $318.3 million, marking a year-over-year decrease of 25.75%. This contributed to the annual value of $5.2 million for FY2019, which is 95.73% down from last year.
- Per Larimar Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $114.0 million for Q3 2020, which was down 9.17% from $125.5 million recorded in Q2 2020.
- Larimar Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $170.0 million during Q1 2016, with a 5-year trough of $5.2 million in Q4 2019.
- For the 3-year period, Larimar Therapeutics' Liabilities and Shareholders Equity averaged around $95.6 million, with its median value being $103.9 million (2019).
- In the last 5 years, Larimar Therapeutics' Liabilities and Shareholders Equity spiked by 37.07% in 2018 and then tumbled by 95.73% in 2019.
- Larimar Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $131.6 million in 2016, then decreased by 19.84% to $105.5 million in 2017, then increased by 15.40% to $121.8 million in 2018, then crashed by 95.73% to $5.2 million in 2019, then climbed by 22.68% to $114.0 million in 2020.
- Its last three reported values are $114.0 million in Q3 2020, $125.5 million for Q2 2020, and $73.7 million during Q1 2020.